GIA announces the
release of a comprehensive global
report on Nanomedicine markets. The global Nanomedicine market continues
to register robust growth largely fueled by unique properties of nanoparticles
that provide novel and improved advantages, introduction of novel products,
healthy rise in funding across the globe, and increased hype around nanotechnology.
Nanomedicine represents a principal domain of nanotechnology that offers capability
to significantly change the course of treatment of life-threatening diseases.
Unlike other therapies, nanomedicine enhances efficacy and significantly minimizes
adversities associated with standard therapeutics. The application of nanotechnology
in the form of nanomedicine in areas including nano drug delivery, nanoanalytical
contrast reagents, nanobiomaterials, and nanopharmaceuticals has been surging
at a stable rate. Recent years saw implementation of several programs by the
industry to bridge the gap between outcomes of clinical research and commercial
products. As a result, the present nanobiomaterial product pipeline poses a
healthy picture with numerous novel products for use in health care applications,
primarily in the form of coatings. Further, research and development in the
nanomedicine market is expected to offer several novel products that can effectively
improve the health of patients suffering from health disorders and illnesses.
Drug delivery market represents the largest application area, while the Biomaterials
segment represents the fastest growing application segment for nanomedicine
over the years 2006 through 2015.
The nanomedicine market is highly fragmented and is characterized by the presence
of several key and niche players. Major market participants in the nanomedicine
market include Abraxis BioScience Inc., AMAG Pharmaceuticals Inc, Arrowhead
Research Corporation, Crucell N.V., Flamel Technologies S.A., Elan Corporation
Plc, Enzon Pharmaceuticals Inc., Life Technologies Corporation, Nanosphere Inc.,
Nektar Therapeutics, Novavax Inc., Oxonica Plc, Par Pharmaceutical Companies
Inc., Starpharma Holdings Limited, and Wyeth Pharmaceuticals Inc., among others.
The report titled "Nanomedicine: A Global Strategic Business Report"
announced by Global Industry Analysts, Inc., covers major market dynamics, trends,
issues, and competition pertaining to the market. Analytical estimates and projections
on market size have been presented in terms of dollar sales over the time period
2006-2015. The report enumerates recent developments, mergers, acquisitions
and other strategic industry activities. The study analyzes the nanomedicine
market by the following application areas - Drug Delivery, In Vitro Diagnostics,
In Vivo Imaging, Biomaterials and Other Applications.